Cost Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England and Wales
Diana Weidlich, Laurent Servais, Imran Kausar, Ruth Howells, Matthias Bischof
doi: https://doi.org/10.1101/2023.02.09.23285715
Diana Weidlich
1Health Economics, Clarivate, Frankfurt am Main, Germany
Laurent Servais
2MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK
3Neuromuscular Center of Liège, Department of Paediatrics, Hospital and University of Liège, Liège, Belgium
Imran Kausar
4Novartis Gene Therapies, London, UK
Ruth Howells
5Health Technology Assessment, Clarivate, Manchester, UK
Matthias Bischof
6Novartis Gene Therapies GmbH, Rotkreuz, Switzerland
Posted February 10, 2023.
Cost Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England and Wales
Diana Weidlich, Laurent Servais, Imran Kausar, Ruth Howells, Matthias Bischof
medRxiv 2023.02.09.23285715; doi: https://doi.org/10.1101/2023.02.09.23285715
Subject Area
Subject Areas
- Addiction Medicine (400)
- Allergy and Immunology (711)
- Anesthesia (204)
- Cardiovascular Medicine (2957)
- Dermatology (250)
- Emergency Medicine (443)
- Epidemiology (12768)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4603)
- Geriatric Medicine (420)
- Health Economics (731)
- Health Informatics (2935)
- Health Policy (1069)
- Hematology (389)
- HIV/AIDS (927)
- Medical Education (429)
- Medical Ethics (116)
- Nephrology (471)
- Neurology (4380)
- Nursing (237)
- Nutrition (640)
- Oncology (2281)
- Ophthalmology (648)
- Orthopedics (258)
- Otolaryngology (326)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (502)
- Pediatrics (1198)
- Primary Care Research (499)
- Public and Global Health (6967)
- Radiology and Imaging (1536)
- Respiratory Medicine (917)
- Rheumatology (442)
- Sports Medicine (385)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)